Cargando…

Myeloproliferative blood cancers as a human neuroinflammation model for development of Alzheimer’s disease: evidences and perspectives

Chronic inflammation and involvement of myeloid blood cells are associated with the development of Alzheimer’s disease (AD). Chronic inflammation is a highly important driving force for the development and progression of the chronic myeloproliferative blood cancers (MPNs), which are characterized by...

Descripción completa

Detalles Bibliográficos
Autores principales:	Hasselbalch, Hans C., Skov, Vibe, Kjær, Lasse, Sørensen, Torben L., Ellervik, Christina, Wienecke, Troels
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2020
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7444051/ https://www.ncbi.nlm.nih.gov/pubmed/32829706 http://dx.doi.org/10.1186/s12974-020-01877-3

Ejemplares similares

Lower CXCR3 expression in both patients with neovascular AMD and advanced stages of chronic myeloproliferative blood cancers
por: Liisborg, Charlotte, et al.
Publicado: (2022)

Retinal drusen in patients with chronic myeloproliferative blood cancers are associated with an increased proportion of senescent T cells and signs of an aging immune system
por: Liisborg, Charlotte, et al.
Publicado: (2021)

JAK2V617F mutation is highly prevalent in patients with ischemic stroke: a case-control study
por: Kristiansen, Marie Hvelplund, et al.
Publicado: (2023)

Serum levels of IL-4, IL-13 and IL-33 in patients with age-related macular degeneration and myeloproliferative neoplasms
por: Gotfredsen, Kathrine, et al.
Publicado: (2023)

Patients with MPNs and retinal drusen show signs of complement system dysregulation and a high degree of chronic low-grade inflammation
por: Liisborg, Charlotte, et al.
Publicado: (2021)

Interferon-alpha2 treatment of patients with polycythemia vera and related neoplasms favorably impacts deregulation of oxidative stress genes and antioxidative defense mechanisms
por: Skov, Vibe, et al.
Publicado: (2022)

Differential Dynamics of CALR Mutant Allele Burden in Myeloproliferative Neoplasms during Interferon Alfa Treatment
por: Kjær, Lasse, et al.
Publicado: (2016)

Elevated levels of oxidized nucleosides in individuals with the JAK2V617F mutation from a general population study
por: Sørensen, Anders L., et al.
Publicado: (2021)

Patients With Myeloproliferative Neoplasms Harbor High Frequencies of CD8 T Cell-Platelet Aggregates Associated With T Cell Suppression
por: Carnaz Simões, Ana Micaela, et al.
Publicado: (2022)

Corrigendum: Patients with myeloproliferative neoplasms harbor high frequencies of CD8 T cell-platelet aggregates associated with T cell suppression
por: Simões, Ana Micaela Carnaz, et al.
Publicado: (2022)

Mathematical modelling as a proof of concept for MPNs as a human inflammation model for cancer development
por: Andersen, Morten, et al.
Publicado: (2017)

Recombinant Interferon-β in the Treatment of Polycythemia Vera and Related Neoplasms: Rationales and Perspectives
por: Hasselbalch, Hans, et al.
Publicado: (2022)

Whole Blood Transcriptional Profiling Reveals Deregulation of Oxidative and Antioxidative Defence Genes in Myelofibrosis and Related Neoplasms. Potential Implications of Downregulation of Nrf2 for Genomic Instability and Disease Progression
por: Hasselbalch, Hans Carl, et al.
Publicado: (2014)

Ocular Manifestations in Patients with Philadelphia-Negative Myeloproliferative Neoplasms
por: Liisborg, Charlotte, et al.
Publicado: (2020)

A novel integrated biomarker index for the assessment of hematological responses in MPNs during treatment with hydroxyurea and interferon‐alpha2
por: Dam, Marc J. B., et al.
Publicado: (2022)

Smoking is associated with increased risk of myeloproliferative neoplasms: A general population‐based cohort study
por: Pedersen, Kasper M., et al.
Publicado: (2018)

Therapeutic cancer vaccination against mutant calreticulin in myeloproliferative neoplasms induces expansion of specific T cells in the periphery but specific T cells fail to enrich in the bone marrow
por: Holmström, Morten Orebo, et al.
Publicado: (2023)

Patients with myeloproliferative neoplasms and high levels of systemic inflammation develop age-related macular degeneration
por: Liisborg, Charlotte, et al.
Publicado: (2020)

HSC Niche Dynamics in Regeneration, Pre-malignancy, and Cancer: Insights From Mathematical Modeling
por: Pedersen, Rasmus Kristoffer, et al.
Publicado: (2022)

Two-fold risk of pneumonia and respiratory mortality in individuals with myeloproliferative neoplasm: A population-based cohort study
por: Pedersen, Kasper Mønsted, et al.
Publicado: (2020)

An arginase1- and PD-L1-derived peptide-based vaccine for myeloproliferative neoplasms: A first-in-man clinical trial
por: Grauslund, Jacob Handlos, et al.
Publicado: (2023)

High frequencies of circulating memory T cells specific for calreticulin exon 9 mutations in healthy individuals
por: Holmström, Morten O., et al.
Publicado: (2019)

Clonal Hematopoiesis and Mutations of Myeloproliferative Neoplasms
por: Kjær, Lasse
Publicado: (2020)

Data‐driven analysis of JAK2V617F kinetics during interferon‐alpha2 treatment of patients with polycythemia vera and related neoplasms
por: Pedersen, Rasmus K., et al.
Publicado: (2020)

Loss-of-function polymorphism in IL6R reduces risk of JAK2V617F somatic mutation and myeloproliferative neoplasm: A Mendelian randomization study
por: Pedersen, Kasper Mønsted, et al.
Publicado: (2020)

Transcriptional Profiling of Whole Blood Identifies a Unique 5-Gene Signature for Myelofibrosis and Imminent Myelofibrosis Transformation
por: Hasselbalch, Hans Carl, et al.
Publicado: (2014)

Elevated white blood cell counts in ischemic stroke patients are associated with increased mortality and new vascular events
por: Vo, Thao Phuong, et al.
Publicado: (2023)

Case Report: First longitudinal study of a patient with CALR positive clonal hematopoiesis of indeterminate potential developing into pre-fibrotic myelofibrosis
por: Kjær, Lasse, et al.
Publicado: (2023)

New Perspectives of Interferon-alpha2 and Inflammation in Treating Philadelphia-negative Chronic Myeloproliferative Neoplasms
por: Hasselbalch, Hans C., et al.
Publicado: (2021)

Perspectives on interferon-alpha in the treatment of polycythemia vera and related myeloproliferative neoplasms: minimal residual disease and cure?
por: Hasselbalch, Hans Carl, et al.
Publicado: (2018)

Ruxolitinib and interferon-α2 combination therapy for patients with polycythemia vera or myelofibrosis: a phase II study
por: Sørensen, Anders Lindholm, et al.
Publicado: (2020)

Mediators of Inflammation in Myeloproliferative Neoplasms: State of the Art
por: Hermouet, Sylvie, et al.
Publicado: (2015)

Myeloproliferative neoplasms in five multiple sclerosis patients()
por: Thorsteinsdottir, Sigrun, et al.
Publicado: (2013)

Revisiting Circulating Extracellular Matrix Fragments as Disease Markers in Myelofibrosis and Related Neoplasms
por: Hasselbalch, Hans Carl, et al.
Publicado: (2023)

COVID-19 as a mediator of interferon deficiency and hyperinflammation: Rationale for the use of JAK1/2 inhibitors in combination with interferon
por: Hasselbalch, H.C., et al.
Publicado: (2021)

Pronounced gut microbiota signatures in patients with JAK2V617F-positive essential thrombocythemia
por: Eickhardt-Dalbøge, Christina Schjellerup, et al.
Publicado: (2023)

The gut microbiota in patients with polycythemia vera is distinct from that of healthy controls and varies by treatment
por: Eickhardt-Dalbøge, Christina Schjellerup, et al.
Publicado: (2022)

Statin treatment, oxidative stress and inflammation in a Danish population
por: Sørensen, Anders L., et al.
Publicado: (2018)

Epigenetic therapy in myeloproliferative neoplasms: evidence and perspectives
por: Vannucchi, Alessandro M, et al.
Publicado: (2009)

Therapeutic Cancer Vaccination With a Peptide Derived From the Calreticulin Exon 9 Mutations Induces Strong Cellular Immune Responses in Patients With CALR-Mutant Chronic Myeloproliferative Neoplasms
por: Handlos Grauslund, Jacob, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_eh2v3v9ro8um29b9ilobflk7u9